Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my post earnings update for NVAX stock.

For the quarter, the S&P 500® Index added 2.41%, while the MSCI EAFE Index slid 8.11%. Click here to read the full commentary ...

GlaxoSmithKline's COVID-19 drive has advanced on two fronts, with the start of phase 3 trials of its Sanofi-partnered vaccine candidate as well as an FDA emergency approval for antibody sotrovimab ...

Sanofi is to take on Boehringer Ingelheim's consumer ... The deal is expected to be finalised by Q4 of 2016 following consultations with unions and employee councils and then clearance from ...

Sanofi India share price gained up to 6% in morning trades on Friday post Q4 results announced by the company after the market hours on Thursday. Sanofi India also announced dividend of ₹117 per share ...

Sanofi Consumer Healthcare India Q4 Results 2025:Sanofi Consumer Healthcare India declared their Q4 results on 20 Feb, 2025. The topline decreased by 20.53% year-over-year (YoY), with profit ...

Novavax reported Q4 sales of $88.31 million ... Since Novavax is reliant on Sanofi’s sales forecasts for certain revenue components, these will not be included in the 2025 Revenue Framework ...

Zacks Research also issued estimates for Sanofi’s Q4 2025 earnings at $0.80 EPS, FY2025 earnings at $4.14 EPS, Q1 2026 earnings at $1.00 EPS, Q3 2026 earnings at $1.36 EPS, Q4 2026 earnings at $ ...

coli disease. Sanofi recorded a $250M impairment charge, lowering Q4 2024 IFRS EPS by €0.15 to €4.44, while business net income and EPS remain unchanged. Our government trade tracker caught ...

With a market valuation of Rs 11,574.76 Cr, Sanofi Indias shares ended Fridays trading session on the BSE 0.58% higher at Rs ...

As a result of the discontinuation, Sanofi has recorded an impairment charge before tax of $250 million in the Q4 2024 IFRS results. This adjustment negatively impacts the full-year IFRS EPS ...